Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT24-OV16/NOVA trial

Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors

“…40 A more recent analysis of NOVA study data found that mean TWiST for patients receiving niraparib was 2.95 years for patients with gBRCA mutations compared with 1.34 years for patients without gBRCA mutations. 41,42 Niraparib treatment of these patient groups produced PFS benefits of 3.23 years and 1.44 years, respectively, and mean toxicity times of 0.28 years and 0.11 years, respectively. QoL remained stable through niraparib treatment and the pre-progression period compared with placebo.…”